Showing 5401-5410 of 9958 results for "".
- Study: Quality, Reliability of TikTok Videos on Spironolactone Is Suspecthttps://practicaldermatology.com/news/Study-Quality-Reliability-TikTok-Videos-Spironolactone-Suspect/2471094/The quality and reliability of information on TikTok regarding spironolactone for acne treatment is concerning, according to a new study by George Washington University researchers. An analysis of the top 50 TikTok videos under the hashtag #spironolactone, which had received 108 million vi
- GW Earns Skin Smart Campus Recognitionhttps://practicaldermatology.com/news/GW-Earns-Skin-Smart-Campus-Recognition/2471093/The National Council on Skin Cancer Prevention recognized George Washington University as a Skin Smart Campus for its ongoing commitment to fostering a safe and healthy learning environment, with a focus on skin cancer prevention and UV safety, the university announced. The Skin Smart Camp
- Higher Complication Rates in Large Skin Reconstructions: Studyhttps://practicaldermatology.com/news/higher-complication-rates-in-large-skin-reconstructions-study/2471062/Large cutaneous reconstructions performed under local anesthesia (including complex linear closures [CLCs], flaps, and grafts) are generally safe but have higher complication rates compared to smaller procedures, a recent study from the University of California, San Diego showed. The retro
- Study Shows Teledermatology Gaining Traction, While Challenges Remainhttps://practicaldermatology.com/news/study-shows-teledermatology-gaining-traction-with-challenges/2471061/Newly published research explored patient perceptions and satisfaction with teledermatology services in the post-pandemic era, showing high satisfaction rates and preferences for hybrid care models. The study surveyed a diverse group of dermatology patients who had utilized teledermatology
- Study: Newer Biologics Do Not Increase MACE/VTE Risk in PsO/PsAhttps://practicaldermatology.com/news/Study-Newer-Biologics-Do-Not-Increase-MACE-VTE-Risk-PsO-PsA/2471065/A new emulated target trial analysis found no significant risk differences in major adverse cardiovascular events (MACE) or venous thromboembolic events (VTE) in patients with psoriasis or psoriatic arthritis treated with IL-17, IL-12/23, or IL-23 inhibitors vs those treated with TNF inhibitors.<
- Study Shows Oral Minoxidil Improves Patient Outcomes for Hair Losshttps://practicaldermatology.com/news/study-shows-oral-minoxidil-improves-patient-outcomes-for-hair-loss/2471041/New research in the Journal of Drugs in Dermatology shows oral minoxidil outperforming topical formulations in terms of patient adherence, satisfaction, and ease of use, without significantly increasing systemic side effects. Researchers on the study studied 50 patients using eith
- Biologic Therapy in Psoriasis: Secukinumab and Ustekinumab Lead in Retentionhttps://practicaldermatology.com/news/biologic-therapy-in-psoriasis-secukinumab-and-ustekinumab-lead-in-retention/2471042/Switching patterns of biologics in psoriasis treatment revealed influences of gender and psoriatic arthritis (PsA), according to new research. The retrospective study from the nationwide digital prescription database of Greece has shed light on biologic treatment trends for psoriasis betwe
- Analysis: Age and Sex Shape Pyogenic Granuloma Patternshttps://practicaldermatology.com/news/analysis-age-and-sex-shape-pyogenic-granuloma-patterns/2471030/An analysis of more than 1,000 pathologically confirmed pyogenic granulomas (PGs) showed distinct age and sex patterns in their distribution, challenging previous understanding of their etiology. Researchers for the analysis examined 1,009 PG cases reported between 2010 and 2020 at a tert
- Study: Safety Signals Emerge for IL-23 and IL-12/23 Inhibitors in Psoriasis Treatmenthttps://practicaldermatology.com/news/safety-signals-emerge-for-il-23-and-il-1223-inhibitors-in-psoriasis-treatment/2470971/A new analysis of psoriasis patients indicates an emergence of new safety signals associated with interleukin-23 (IL-23) inhibitors and the IL-12/23 inhibitor ustekinumab. Researchers on the study analyzed 41.4 million adverse event (AE) reports from the FDA Adverse Event Reporting System
- Study: Higher Isotretinoin Doses Reduce Acne Relapse Riskhttps://practicaldermatology.com/news/study-higher-isotretinoin-doses-reduce-acne-relapse-risk/2470951/Results from a new cohort study show higher cumulative isotretinoin dosages are associated with lower rates of acne relapse and retreatment, and that daily dosing does not influence these outcomes for patients on conventional or high cumulative doses. Authors on the study analyzed data fro